Compare Lupin Ltd with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs PIRAMAL ENTERPRISES - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN PIRAMAL ENTERPRISES LUPIN/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 47.5 17.6 269.9% View Chart
P/BV x 2.4 1.1 217.9% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 LUPIN   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    LUPIN
Mar-19
PIRAMAL ENTERPRISES
Mar-19
LUPIN/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs9863,303 29.9%   
Low Rs7201,797 40.1%   
Sales per share (Unadj.) Rs369.5716.5 51.6%  
Earnings per share (Unadj.) Rs13.479.7 16.8%  
Cash flow per share (Unadj.) Rs37.4107.9 34.6%  
Dividends per share (Unadj.) Rs028.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs303.71,477.5 20.6%  
Shares outstanding (eoy) m452.49184.45 245.3%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.33.6 64.9%   
Avg P/E ratio x63.632.0 199.0%  
P/CF ratio (eoy) x22.823.6 96.6%  
Price / Book Value ratio x2.81.7 162.8%  
Dividend payout %035.1 0.0%   
Avg Mkt Cap Rs m386,064470,292 82.1%   
No. of employees `00017.77.8 226.1%   
Total wages/salary Rs m31,51322,504 140.0%   
Avg. sales/employee Rs Th9,453.816,899.4 55.9%   
Avg. wages/employee Rs Th1,782.02,877.7 61.9%   
Avg. net profit/employee Rs Th343.01,879.9 18.2%   
INCOME DATA
Net Sales Rs m167,182132,153 126.5%  
Other income Rs m3,6403,128 116.4%   
Total revenues Rs m170,822135,281 126.3%   
Gross profit Rs m28,82266,290 43.5%  
Depreciation Rs m10,8505,202 208.6%   
Interest Rs m3,07844,097 7.0%   
Profit before tax Rs m18,53420,119 92.1%   
Minority Interest Rs m-893,194 -2.8%   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,0178,611 104.7%   
Profit after tax Rs m6,06614,701 41.3%  
Gross profit margin %17.250.2 34.4%  
Effective tax rate %48.742.8 113.7%   
Net profit margin %3.611.1 32.6%  
BALANCE SHEET DATA
Current assets Rs m138,536122,742 112.9%   
Current liabilities Rs m61,299310,810 19.7%   
Net working cap to sales %46.2-142.3 -32.5%  
Current ratio x2.30.4 572.3%  
Inventory Days Days8423 363.2%  
Debtors Days Days11239 289.5%  
Net fixed assets Rs m127,516116,904 109.1%   
Share capital Rs m905369 245.3%   
"Free" reserves Rs m136,517272,161 50.2%   
Net worth Rs m137,422272,530 50.4%   
Long term debt Rs m66,417270,196 24.6%   
Total assets Rs m279,494856,261 32.6%  
Interest coverage x7.01.5 482.1%   
Debt to equity ratio x0.51.0 48.7%  
Sales to assets ratio x0.60.2 387.6%   
Return on assets %3.36.9 47.6%  
Return on equity %4.45.4 81.8%  
Return on capital %8.912.4 71.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41415,200 390.9%   
Fx outflow Rs m22,2824,889 455.8%   
Net fx Rs m37,13210,312 360.1%   
CASH FLOW
From Operations Rs m16,660-115,975 -14.4%  
From Investments Rs m-32,825-8,265 397.1%  
From Financial Activity Rs m7,441107,525 6.9%  
Net Cashflow Rs m-8,724-16,650 52.4%  

Share Holding

Indian Promoters % 46.6 52.9 88.1%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 4.0 282.5%  
FIIs % 31.9 26.6 119.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 16.5 61.2%  
Shareholders   98,259 93,274 105.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Sep 19, 2019 (Close)

TRACK LUPIN

LUPIN - TORRENT PHARMA COMPARISON

COMPARE LUPIN WITH

MARKET STATS